Intralesional treatment of metastatic melanoma: a review of therapeutic options

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2017-01-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-016-1952-0PMID 28078357PMCID PMC6126622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vaccine adjuvants as potential cancer immunotherapeutics

  2016cited by this paper
• A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265).

  2016cited by this paper
• A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach.

  2016cited by this paper
• Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

  2016cited by this paper
• Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

  2016cited by this paper
• Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

  2015cited by this paper
• Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

  2015cited by this paper
• Therapeutic Advances and Treatment Options in Metastatic Melanoma.

  2015cited by this paper
• Oncolytic viruses: a new class of immunotherapy drugs

  2015cited by this paper
• Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

  2015cited by this paper
• Intralesional therapy for advanced melanoma: promise and limitation

  2015cited by this paper
• Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy

  2014cited by this paper
• Topical treatment of melanoma skin metastases with imiquimod: a review.

  2014cited by this paper
• Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

  2014cited by this paper
• Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma

  2014cited by this paper
• Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

  2014cited by this paper
• Intratumoral Immunization: A New Paradigm for Cancer Therapy

  2014cited by this paper
• Locoregional therapies in melanoma.

  2014cited by this paper
• CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

  2014cited by this paper
• Isolated limb perfusion with the tumor‐targeting human monoclonal antibody–cytokine fusion protein L19‐TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma

  2013cited by this paper
• Aldara activates TLR7-independent immune defence

  2013cited by this paper
• Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

  2013cited by this paper
• Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours

  2013cited by this paper
• The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.

  2013cited by this paper
• Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil

  2012cited by this paper
• Combined Intralesional Bacille Calmette-Guérin (BCG) and Topical Imiquimod for In-transit Melanoma

  2012cited by this paper
• Intra‐lesional interleukin‐2 for the treatment of in‐transit melanoma

  2011cited by this paper
• A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

  2011cited by this paper
• High response rate after intratumoral treatment with interleukin‐2

  2010cited by this paper
• The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

  2010cited by this paper
• Experiencia en el tratamiento de satelitosis y metástasis cutáneas en tránsito de melanoma con interleucina 2 intralesional

  2009cited by this paper
• Topical diphencyprone immunotherapy for cutaneous metastatic melanoma

  2009cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].

  2009cited by this paper
• Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

  2009cited by this paper
• Improved survival for stage IV melanoma from an unknown primary site.

  2009cited by this paper
• Chemoablation of metastatic melanoma using intralesional Rose Bengal

  2008cited by this paper
• Systemic Phototoxicity following Intralesional Rose Bengal for Subcutaneous Melanoma Metastases

  2008cited by this paper
• Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma

  2008cited by this paper
• Rose Bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma

  2006cited by this paper
• Antibody targeted drugs as cancer therapeutics

  2006cited by this paper
• TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.

  2006cited by this paper
• A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor

  2006cited by this paper
• Contemporary surgical treatment of advanced-stage melanoma.

  2004cited by this paper
• Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673)

  2004cited by this paper
• Imiquimod: modes of action.

  2003cited by this paper
• Epidemiology of melanoma and nonmelanoma skin cancer.

  2003cited by this paper
• Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

  2003cited by this paper
• Onychomycosis in clinical practice: factors contributing to recurrence.

  2003cited by this paper
• Imiquimod: modes of action

  2003cited by this paper
• ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

  2003cited by this paper
• Clinical and Laboratory Investigations Metastatic pathways and time courses in the orderly progression of cutaneous melanoma

  2002cited by this paper
• Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway

  2002cited by this paper
• The therapeutic use of topical contact sensitizers in benign dermatoses

  2001cited by this paper
• The therapeutic use of topical contact sensitizers in benign dermatoses.

  2001cited by this paper
• Imiquimod applied topically: a novel immune response modifier and new class of drug.

  1999cited by this paper
• Suppression of the phenotype of gamma(1)34.5- herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene

  1997cited by this paper
• Topical immunotherapy of alopecia areata.

  1996cited by this paper
• The role of adjuvant therapy in melanoma management

  1995cited by this paper
• Perilumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma

  1994cited by this paper
• Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma.

  1994cited by this paper
• Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

  1989cited by this paper
• Risks of BCG intralesional therapy: An experience with melanoma

  1977cited by this paper
• BCG immunotherapy in patients with malignant melanoma.

  1976cited by this paper
• Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.

  1975cited by this paper
• Regression of pulmonary metastatic disease associated with intralesional bcg therapy of intracutaneous melanoma metastases

  1975cited by this paper
• A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach.

  1974cited by this paper

• Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies

  2025cites this paper
• Melanoma neoadjuvant treatment: review and update of recent trials

  2025cites this paper
• An intralesional approach with oncolytic viral and immunologic melanoma therapy

  2025cites this paper
• Analyzing the mechanism by which oyster peptides target IL-2 in melanoma cell apoptosis based on RNA-seq and m6A-seq.

  2023cites this paper
• Cytokine Storm Due to Intralesional Intelukin-2 Therapy for Cutaneous In-Transit Melanoma

  2023cites this paper
• Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications

  2022cites this paper
• Development of chitosan, pullulan, and alginate based drug-loaded nano-emulsions as a potential malignant melanoma delivery platform

  2022cites this paper
• Intratumorally anchored cytokine therapy

  2022cites this paper
• Oncolytic virus: A catalyst for the treatment of gastric cancer

  2022cites this paper
• DNA binding and evaluation of anticancer activity in vitro and in vivo of iridium(III) polypyridyl complexes.

  2021cites this paper
• Inference of molecular structure for characterization and improvement of clinical grade immunocytokines.

  2021cites this paper
• Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma

  2021cites this paper
• Current approaches in managing in-transit metastasis of malignant melanoma: a comprehensive review and proposal of an algorithm

  2021influential citation
• Local and Recurrent Regional Metastases of Melanoma

  2020cites this paper
• Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives

  2020cites this paper
• Engineering IL-2 to Give New Life to T Cell Immunotherapy.

  2020cites this paper
• Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors

  2020cites this paper
• ASO Author Reflection: Isolated Limb Infusion for Locally Advanced Melanoma in the Extremely Old Patient is Safe and Effective

  2020cites this paper
• International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients

  2020cites this paper
• Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma

  2020cites this paper
• Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

  2019cites this paper
• Topical and intralesional therapies for in-transitmelanoma

  2019cites this paper
• Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy.

  2019cites this paper
• First Eastern European experience of isolated limb infusion for in-transit metastatic melanoma confined to the limb: Is it still an effective treatment option in the modern era?

  2019cites this paper
• Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy

  2019cites this paper
• Local and Recurrent Regional Metastases of Melanoma

  2019cites this paper
• Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone

  2019cites this paper
• Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China

  2018cites this paper
• Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity.

  2018cites this paper
• Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy

  2018cites this paper
• Management of local or regional non‐nodal disease

  2018cites this paper
• How to use neoadjuvant medical treatment to maximize surgery in melanoma

  2018cites this paper
• Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab

  2017cites this paper
• Solanum incanum extract (SR-T100) induces melanoma cell apoptosis and inhibits established lung metastasis

  2017cites this paper
• Microradiopharmaceutical for Metastatic Melanoma

  2017cites this paper
• Tumor-related interleukins: old validated targets for new anti-cancer drug development

  2017cites this paper
• Dermatologic Toxicities of Anticancer Therapy

  2014cites this paper
• MIT Open Access Articles Intratumorally anchored cytokine therapy

  year unknowncites this paper